THALASSEMIA INTERNATIONAL FEDERATION TO DEPLOY FERRISMART
- 15 November 2021
Resonance Health Ltd has today signed a Patient Access to FerriSmart® Letter of Agreement with the World Health Organization related Cyprus based Thalassaemia International Federation (TIF).
Introducing LiverSmart: A New AI Medical Device
- 13 October 2021
Resonance Health Ltd announces the development of its newest AI medical device, LiverSmart, which is now undergoing final quality and verification checks prior to its submission to the United States Food & Drug Administration (FDA) for regulatory clearance.
LiverSmart combines two existing regulatory-cleared Resonance Health products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, avoiding the need for multiple MRI appointments, and delivering a more complete and comprehensive assessment of a person’s liver.
EASL Digital #NAFLDSummit 2021: Resonance Health presents, HepaFat-AI results equivalent to a conventional MRS technique
- 24 September 2021
Resonance Health attended the EASL Digital NAFLD Summit 2021 on 16 – 17 September and participated with insights into developments in artificial intelligence-based approaches to NAFLD management using HepaFat-AI.
Appointment of GM - Global Sales & Marketing
- 28 July 2021
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that Mr. Ajay Nair has been appointed to the new role of General Manager - Global Sales & Marketing.
Resonance Health News - June 2021
- 18 June 2021
Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities.
To read the newsletter please click here
Appointment of Chief Financial Officer & Company Secretary
- 08 April 2021
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021.